Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Radiotherapy for Adjuvant Treatment of HER2+ UTUC
NCT06210490Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2024
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in upper urinary tract urothelial carcinoma (UTUC), sponsored by Peking University First Hospital. Started Feb 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
upper urinary tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06210490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210490.